A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Summary

Phase II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) combined with Docetaxel in Advanced Non-Small Cell Lung Cancer whose disease has progressed after prior platinum doublet chemotherapy and anti-PD-1/PD-L1 monoclonal antibody

Timeline

Start

2022-05-13

Primary completion

2026-01-30

Completion

2026-01-30

Drugs

Indications